Nanocarriers for vascular delivery of anti-inflammatory agents

Annual Review of Pharmacology and Toxicology

Volumn 54, Issue , 2014, Pages 205-226

  Howard, Melissa D ^a   Hood, Elizabeth D ^a   Zern, Blaine ^a   Shuvaev, Vladimir V ^a   Grosser, Tilo ^a   Muzykantov, Vladimir R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cell adhesion molecules; Endothelium; Intracellular delivery; Liposomes; Polymeric nanocarriers; Vascular immunotargeting

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; GLUCOCORTICOID; NANOCARRIER; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; SMALL INTERFERING RNA;

BLOOD VESSEL TONE; CELL COMPARTMENTALIZATION; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; ENDOTHELIUM CELL; INFLAMMATION; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; NANOSTRUCTURES; VASCULAR DISEASES;

EID: 84891855568     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011613-140002     Document Type: Review

References (117)

1. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. 2012. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338:903-10
2. Casi G, Neri D. 2012. Antibody-drug conjugates: basic concepts, examples and future perspectives. J. Control. Release 161:422-28
3. White CW, Jackson JH, Abuchowski A, Kazo GM, Mimmack RF, et al. 1989. Polyethylene glycol-attached antioxidant enzymes decrease pulmonary oxygen toxicity in rats. J. Appl. Physiol. 66:584-90
4. Kirby C, Gregoriadis G. 1984. Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Nat. Biotechnol. 2:979-84
5. Klibanov AL, Maruyama K, Torchilin VP, Huang L. 1990. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:235-37
6. Howard MD, Jay M, Dziubla TD, Lu X. 2008. PEGylation of nanocarrier drug delivery systems: state of the art. J. Biomed. Nanotechnol. 4:133-48
7. Hristova K, Kenworthy A, McIntosh TJ. 1995. Effect of bilayer composition on the phase behavior of liposomal suspensions containing poly(ethylene glycol)-lipids. Macromolecules 28:7693-99
8. Barenholz Y. 2012. DoxilR®-The first FDA-approved nano-drug: lessons learned. J. Control. Release 160:117-34
9. Kheradmandnia S, Vasheghani-Farahani E, Nosrati M, Atyabi F. 2010. Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomed.: Nanotechnol. Biol. Med. 6:753-59
10. Wissing SA, Kayser O, Müller RH. 2004. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56:1257-72
11. Chorny M, Fishbein I, Yellen BB, Alferiev IS, Bakay M, et al. 2010. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc. Natl. Acad. Sci. USA 107:8346-51
12. Misra AC, Bhaskar S, Clay N, Lahann J. 2012. Multicompartmental particles for combined imaging and siRNA delivery. Adv. Mater. 24:3850-56
13. Pochan DJ, Zhu J, Zhang K, Wooley KL, Miesch C, Emrick T. 2011. Multicompartment and multigeometry nanoparticle assembly. Soft Matter 7:2500-6
14. Labouta HI, Schneider M. 2010. Tailor-made biofunctionalized nanoparticles using layer-by-layer technology. Int. J. Pharm. 395:236-42
15. Kohler D, Madaboosi N, Delcea M, Schmidt S, De Geest BG, et al. 2012. Patchiness of embedded particles and film stiffness control through concentration of gold nanoparticles. Adv. Mater. 24:1095-100
16. Guillaudeu SJ, Fox ME, Haidar YM, Dy EE, Szoka FC, Fréchet JMJ. 2008. PEGylated dendrimers with core functionality for biological applications. Bioconjug. Chem. 19:461-69
17. Kataoka K, Harada A, Nagasaki Y. 2001. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47:113-31
18. Nicolai T, Colombani O, Chassenieux C. 2010. Dynamic polymeric micelles versus frozen nanoparticles formed by block copolymers. Soft Matter 6:3111-18
19. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, et al. 2007. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2:249-55
20. Simone EA, Dziubla TD, Colon-Gonzalez F, Discher DE, Muzykantov VR. 2007. Effect of polymer amphiphilicity on loading of a therapeutic enzyme into protective filamentous and spherical polymer nanocarriers. Biomacromolecules 8:3914-21
21. Merkel TJ, Jones SW, Herlihy KP, Kersey FR, Shields AR, et al. 2011. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc. Natl. Acad. Sci. USA 108:586-91
22. Champion JA, Mitragotri S. 2006. Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. USA 103:4930-34
23. 99mTc-labeled folate conjugate targeted to folate receptor positive macrophages. Mol. Pharm. 9:1435-40
24. Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, et al. 2011. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29:1005-10
25. Shuvaev VV, Muzykantov VR. 2011. Targeted modulation of reactive oxygen species in the vascular endothelium. J. Control. Release 153:56-63
26. Pober JS, Sessa WC. 2007. Evolving functions of endothelial cells in inflammation. Nat. Rev. Immunol. 7:803-15
27. Simone E, Ding BS, Muzykantov V. 2009. Targeted delivery of therapeutics to endothelium. Cell Tissue Res. 335:283-300
28. Shuvaev VV, Christofidou-Solomidou M, Bhora F, Laude K, Cai H, et al. 2009. Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J. Pharmacol. Exp. Ther. 331:404-11
29. Danielyan K, Ding B-S, Gottstein C, Cines DB, Muzykantov VR. 2007. Delivery of anti-plateletendothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema. J. Pharmacol. Exp. Ther. 321:947-52
30. Scherpereel A, Rome JJ, Wiewrodt R, Watkins SC, Harshaw DW, et al. 2002. Platelet-endothelial cell adhesion molecule-1-directed immunotargeting to cardiopulmonary vasculature. J. Pharmacol. Exp. Ther. 300:777-86
31. Zhou H-f, Hu G, Wickline SA, Lanza GM, Pham CTN. 2010. Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis. Nanomedicine 5:1065-74
32. Muzykantov VR. 2005. Biomedical aspects of targeted delivery of drugs to pulmonary endothelium. Expert Opin. Drug Deliv. 2:909-26
33. Spragg DD, Alford DR, Greferath R, Larsen CE, Lee K-D, et al. 1997. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc. Natl. Acad. Sci. USA 94:8795-800
34. Ásgeirsdóttir SA, Kamps JAAM, Bakker HI, Zwiers PJ, Heeringa P, et al. 2007. Site-specific inhibition of glomerulonephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol. Pharmacol. 72:121-31
35. Calderon AJ, Muzykantov V, Muro S, Eckmann DM. 2009. Flow dynamics, binding and detachment of spherical carriers targeted to ICAM-1 on endothelial cells. Biorheology 46:323-41
36. Calderon AJ, Bhowmick T, Leferovich J, Burman B, Pichette B, et al. 2011. Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers. J. Control. Release 150:37-44
37. Hak S, Helgesen E, Hektoen HH, Huuse EM, Jarzyna PA, et al. 2012. The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in vivo by dual modality imaging. ACS Nano 6:5648-58
38. Fakhari A, Baoum A, Siahaan TJ, Le KB, Berkland C. 2011. Controlling ligand surface density optimizes nanoparticle binding to ICAM-1. J. Pharm. Sci. 100:1045-56
39. Zern BJ, Chacko A-M, Liu J, Greineder CF, Blankemeyer ER, et al. 2013. Reduction of nanoparticle avidity enhances the selectivity of vascular targeting and PET detection of pulmonary inflammation. ACS Nano 7:2461-69
40. Shuvaev VV, Tliba S, Pick J, Arguiri E, Christofidou-Solomidou M, et al. 2011. Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates. J. Control. Release 149:236-41
41. Shuvaev VV, Ilies MA, Simone E, Zaitsev S, Kim Y, et al. 2011. Endothelial targeting of antibodydecorated polymeric filomicelles. ACS Nano 5:6991-99
42. Muro S, Garnacho C, Champion JA, Leferovich J, Gajewski C, et al. 2008. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol. Ther. 16:1450-58
43. Oh P, Borgstrom P, Witkiewicz H, Li Y, Borgstrom BJ, et al. 2007. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat. Biotechnol. 25:327-37
44. Muro S, Wiewrodt R, Thomas A, Koniaris L, Albelda SM, et al. 2003. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J. Cell Sci. 116:1599-609
45. Muro S, Cui X, Gajewski C, Murciano J-C, Muzykantov VR, Koval M. 2003. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am. J. Physiol. Cell Physiol. 285:C1339-47
46. Garnacho C, Albelda SM, Muzykantov VR, Muro S. 2008. Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. J. Control. Release 130:226-33
47. Bhowmick T, Berk E, Cui X, Muzykantov VR, Muro S. 2012. Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1. J. Control. Release 157:485-92
48. Han J, Zern BJ, Shuvaev VV, Davies PF, Muro S, Muzykantov V. 2012. Acute and chronic shear stress differently regulate endothelial internalization of nanocarriers targeted to platelet-endothelial cell adhesion molecule-1. ACS Nano 6:8824-36
49. Quan LD, Thiele GM, Tian J, Wang D. 2008. The development of novel therapies for rheumatoid arthritis. Expert Opin. Ther. Pat. 18:723-38
50. Bonanomi MH, Velvart M, Stimpel M, Roos KM, Fehr K, Weder HG. 1987. Studies of pharmacokinetics and therapeutic effects of glucocorticoids entrapped in liposomes after intraarticular application in healthy rabbits and in rabbits with antigen-induced arthritis. Rheumatol. Int. 7:203-12
51. Hegeman MA, Cobelens PM, Kamps JAAM, Hennus MP, Jansen NJG, et al. 2011. Liposomeencapsulated dexamethasone attenuates ventilator-induced lung inflammation. Br. J. Pharmacol. 163:1048-58
52. Suntres ZE, Shek PN. 2000. Prophylaxis against lipopolysaccharide-induced lung injuries by liposomeentrapped dexamethasone in rats. Biochem. Pharmacol. 59:1155-61
53. Rauchhaus U, Schwaiger FW, Panzner S. 2009. Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment. Arthritis Res. Ther. 11:R190
54. Koning GA, Schiffelers RM, Wauben MHM, Kok RJ, Mastrobattista E, et al. 2006. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum. 54:1198-208
55. Everts M, Koning GA, Kok RJ, Ásgeirsdóttir SA, Vestweber D, et al. 2003. In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. Pharm. Res. 20:64-72
56. Ulmansky R, Turjeman K, Baru M, Katzavian G, Harel M, et al. 2012. Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. J. Control. Release 160:299-305
57. Xiang QY, Wang MT, Chen F, Gong T, Jian YL, et al. 2007. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch. Pharm. Res. 30:519-25
58. Zhang Z, Grijpma DW, Feijen J. 2006. Poly(trimethylene carbonate) and monomethoxy poly(ethylene glycol)-block-poly(trimethylene carbonate) nanoparticles for the controlled release of dexamethasone. J. Control. Release 111:263-70
59. Puri S, Kallinteri P, Higgins S, Hutcheon GA, Garnett MC. 2008. Drug incorporation and release of water soluble drugs from novel functionalized poly(glycerol adipate) nanoparticles. J. Control. Release 125:59-67
60. Kim JY, Ryu JH, Hyun H, Kim HA, Sig Choi J, et al. 2012. Dexamethasone conjugation to polyamidoamine dendrimers G1 and G2 for enhanced transfection efficiency with an anti-inflammatory effect. J. Drug Target. 20:667-77
61. Ishihara T, Kubota T, Choi T, Higaki M. 2009. Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J. Pharmacol. Exp. Ther. 329:412-17
62. Ishihara T, Kubota T, Choi T, Takahashi M, Ayano E, et al. 2009. Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness. Int. J. Pharm. 375:148-54
63. Wang D, Miller S, Liu X-M, Anderson B, Wang XS, Goldring S. 2007. Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res. Ther. 9:R2
64. Krakovicová H, Etrych T, Ulbrich K. 2009. HPMA-based polymer conjugates with drug combination. Eur. J. Pharm. Sci. 37:405-12
65. Howard M, Ponta A, Eckman A, Jay M, Bae Y. 2011. Polymermicelles with hydrazone-ester dual linkers for tunable release of dexamethasone. Pharm. Res. 28:2435-46
66. Lu X, Howard MD, Talbert DR, Rinehart JJ, Potter PM, et al. 2009. Nanoparticles containing antiinflammatory agents as chemotherapy adjuvants II: role of plasma esterases in drug release. AAPS J. 11:120-22
67. Chandrasekar D, Sistla R, Ahmad FJ, Khar RK, Diwan PV. 2007. The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials 28:504-12
68. Bernardi A, Zilberstein A, Jäger E, Campos MM, Morrone FB, et al. 2009. Effects of indomethacinloaded nanocapsules in experimental models of inflammation in rats. Br. J. Pharmacol. 158:1104-11
69. Bernardi A, Frozza RL, Meneghetti A, Hoppe JB, Battastini AMO, et al. 2012. Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer's disease models. Int. J. Nanomed. 7:4927-42
70. Prajapati RN, Tekade RK, Gupta U, Gajbhiye V, Jain NK. 2009. Dendrimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. Mol. Pharm. 6:940-50
71. Ianiski FR, Alves CB, Souza ACG, Pinton S, Roman SS, et al. 2012. Protective effect of meloxicam-loaded nanocapsules against amyloid- βpeptide-induced damage in mice. Behav. Brain Res. 230:100-7
72. Liu X, Miller MJS, Joshi MS, Sadowska-Krowicka H, Clark DA, Lancaster JR. 1998. Diffusion-limited reaction of free nitric oxide with erythrocytes. J. Biol. Chem. 273:18709-13
73. Nacharaju P, Tuckman-Vernon C, Maier KE, Chouake J, Friedman A, et al. 2012. A nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine: sustained vascular response. Nitric Oxide 27:150-60
74. Stasko NA, Schoenfisch MH. 2006. Dendrimers as a scaffold for nitric oxide release. J. Am. Chem. Soc. 128:8265-71
75. Kumar V, Hong SY, Maciag AE, Saavedra JE, Adamson DH, et al. 2009. Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles. Mol. Pharm. 7:291-98
76. Cabrales P, Han G, Roche C, Nacharaju P, Friedman AJ, Friedman JM. 2010. Sustained release nitric oxide from long-lived circulating nanoparticles. Free Radic. Biol. Med. 49:530-38
77. Johnson TA, Stasko NA, Matthews JL, Cascio WE, Holmuhamedov EL, et al. 2010. Reduced ischemia/reperfusion injury via glutathione-initiated nitric oxide-releasing dendrimers. Nitric Oxide 22:30-36
78. Muzykantov VR. 2010. NO gets a test ride on high-tech transporting nanodevices: a commentary on "Sustained-release nitric oxide from long-lived circulating nanoparticles." Free Radic. Biol. Med. 49:528-29
79. Christofidou-Solomidou M, Muzykantov VR. 2006. Antioxidant strategies in respiratory medicine. Treat. Respir. Med. 5:47-78
80. Muzykantov VR. 2001. Delivery of antioxidant enzyme proteins to the lung. Antioxid. Redox Signal. 3:39-62
81. Fleming C, Maldjian A, Da Costa D, Rullay AK, Haddleton DM, et al. 2005. A carbohydrate-antioxidant hybrid polymer reduces oxidative damage in spermatozoa and enhances fertility. Nat. Chem. Biol. 1:270-74
82. Williams SR, Lepene BS, Thatcher CD, Long TE. 2009. Synthesis and characterization of poly(ethylene glycol)-glutathione conjugate self-assembled nanoparticles for antioxidant delivery. Biomacromolecules 10:155-61
83. Astete CE, Dolliver D, Whaley M, Khachatryan L, Sabliov C. 2011. Antioxidant poly(lactic-co-glycolic) acid nanoparticles made with α-tocopherol-ascorbic acid surfactant. ACS Nano 5:9313-25
84. Hood E, Simone E, Wattamwar P, Dziubla T, Muzykantov V. 2011. Nanocarriers for vascular delivery of antioxidants. Nanomedicine 6:1257-72
85. Stone WL, Smith M. 2004. Therapeutic uses of antioxidant liposomes. Mol. Biotechnol. 27:217-30
86. Mitsopoulos P, Omri A, Alipour M, Vermeulen N, Smith MG, Suntres ZE. 2008. Effectiveness of liposomal-N-acetylcysteine against LPS-induced lung injuries in rodents. Int. J. Pharm. 363:106-11
87. Fan J, Shek PN, Suntres ZE, Li YH, Oreopoulos GD, Rotstein OD. 2000. Liposomal antioxidants provide prolonged protection against acute respiratory distress syndrome. Surgery 128:332-38
88. Hung CF, Chen JK, Liao MH, Lo HM, Fang JY. 2006. Development and evaluation of emulsionliposome blends for resveratrol delivery. J. Nanosci. Nanotechnol. 6:2950-58
89. 2 toxicity in the newborn rat. J. Appl. Physiol. 63:347-52
90. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. 1997. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95:588-93
91. Corvo LM, Jorge JCS, van't Hof R, Cruz MEM, Crommelin DJA, Storm G. 2002. Superoxide dismutase entrapped in long-circulating liposomes: formulation design and therapeutic activity in rat adjuvant arthritis. Biochim. Biophys. Acta (BBA): Biomembr. 1564:227-36
92. Xu X, Costa A, Burgess DJ. 2012. Protein encapsulation in unilamellar liposomes: high encapsulation efficiency and a novel technique to assess lipid-protein interaction. Pharm. Res. 29:1919-31
93. Gaspar MM, Boerman OC, Laverman P, Corvo ML, Storm G, Cruz ME. 2007. Enzymosomes with surface-exposed superoxide dismutase: in vivo behaviour and therapeutic activity in a model of adjuvant arthritis. J. Control. Release 117:186-95
94. Yan M, Du JJ, Gu Z, Liang M, Hu YF, et al. 2010. A novel intracellular protein delivery platform based on single-protein nanocapsules. Nat. Nanotechnol. 5:48-53
95. Brynskikh AM, Zhao Y, Mosley RL, Li S, Boska MD, et al. 2010. Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine 5:379-96
96. Rosenbaugh EG, Roat JW, Gao L, Yang RF, Manickam DS, et al. 2010. The attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase. Biomaterials 31:5218-26
97. Yi X, Zimmerman MC, Yang R, Tong J, Vinogradov S, Kabanov AV. 2010. Pluronic-modified superoxide dismutase 1 attenuates angiotensin II-induced increase in intracellular superoxide in neurons. Free Radic. Biol. Med. 49:548-58
98. Shuvaev VV, Han J, Yu KJ, Huang S, Hawkins BJ, et al. 2011. PECAM-targeted delivery of SODinhibits endothelial inflammatory response. FASEB J. 25:348-57
99. +/H+ exchanger proteins. Am. J. Physiol. Lung Cell. Mol. Physiol. 290:L809-17
100. Giovagnoli S, Luca G, Casaburi I, Blasi P, Macchiarulo G, et al. 2005. Long-term delivery of superoxide dismutase and catalase entrapped in poly(lactide-co-glycolide) microspheres: in vitro effects on isolated neonatal porcine pancreatic cell clusters. J. Control. Release 107:65-77
101. Dziubla TD, Karim A, Muzykantov VR. 2005. Polymer nanocarriers protecting active enzyme cargo against proteolysis. J. Control. Release 102:427-39
102. Dziubla TD, Shuvaev VV, Hong NK, Hawkins BJ, Madesh M, et al. 2008. Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials 29:215-27
103. Chorny M, Fishbein I, Alferiev I, Levy RJ. 2009. Magnetically responsive biodegradable nanoparticles enhance adenoviral gene transfer in cultured smoothmuscle and endothelial cells. Mol. Pharm. 6:1380-87
104. Chorny M, Hood E, Levy RJ, Muzykantov VR. 2010. Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. J. Control. Release 146:144-51
105. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-11
106. Whitehead KA, Langer R, Anderson DG. 2009. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8:129-38
107. Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, et al. 2007. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25:1149-57
108. Yuan X, Naguib S, Wu Z. 2011. Recent advances of siRNA delivery by nanoparticles. Expert Opin. Drug Deliv. 8:521-36
109. Davis ME. 2009. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6:659-68
110. Kuldo JM, Ogawara KI, Werner N, Ásgeirsdóttir SA, Kamps JAAM, et al. 2005. Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases. Curr. Vasc. Pharmacol. 3:11-39
111. Zheng X, Vladau C, Shunner A, Min WP. 2010. siRNA specific delivery system for targeting dendritic cells. Methods Mol. Biol. 623:173-88
112. Nishiwaki Y, Yokota T, Hiraoka M, Miyagishi M, Taira K, et al. 2003. Introduction of short interfering RNAto silence endogenous E-selectin in vascular endothelium leads to successful inhibition of leukocyte adhesion. Biochem. Biophys. Res. Commun. 310:1062-66
113. Vader P, Crielaard BJ, van Dommelen SM, van der Meel R, Storm G, Schiffelers RM. 2012. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles. J. Control. Release 160:211-16
114. Kuldo JM, Ásgeirsdóttir SA, Zwiers PJ, Bellu AR, Rots MG, et al. 2013. Targeted adenovirus mediated inhibition of NF-κB-dependent inflammatory gene expression in endothelial cells in vitro and in vivo. J. Control. Release 166:57-65
115. Ásgeirsdóttir SA, Talman EG, de Graaf IA, Kamps JAAM, Satchell SC, et al. 2010. Targeted transfection increases siRNA uptake and gene silencing of primary endothelial cells in vitro-a quantitative study. J. Control. Release 141:241-51
116. Zuckerman JE, Choi CHJ, Han H, Davis ME. 2012. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc. Natl. Acad. Sci. USA 109:3137-42
117. Lee JB, Zhang K, Tam YYC, Tam YK, Belliveau NM, et al. 2012. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int. J. Cancer 131:E781-90